Paulo R. De Alcantara Filho, Stephania Martins Bezerra

1Breast Surgery Department, Hospital Sirio-Libanes, Sao Paulo 01308-050, Brazil.

2Pathology Department, ACCamargo Cancer Center, Sao Paulo 01509-010, Brazil.

Abstract Axillary recurrence is a rare event in patients treated with sentinel lymph node biopsy alone with the majority occurring in the first 5 years after surgery. Intramammary lymph node (IMLN) can be the primary sites of metastasis and sentinel lymph nodes, but the clinical significance, including prognosis and therapeutic approach is yet unclear, even more with capsular extravasation. IMLN metastases are strongly correlated with axillary lymph nodes involvement and therefore a guide for further surgical management of the axillary nodes.

Keywords: Breast cancer, sentinel lymph node, lymph node dissection, metastasis, locoregional neoplasm recurrence

INTRODUCTION

Reported series of patients with intramammary lymph node (IMLN) diagnosed by final histological examination are small in number and clinical significance of metastasis is still unclear[1]. We previously reported a case of conservative breast cancer surgery with 3 positive IMLNs demonstrating extracapsular extravasation (ECE). After multidisciplinary discussion, the patient was submitted to mastectomy and no further axillary dissection. Even though the 3 IMLNs were positive, pathology examination did not reveal any signs of malignancy in the mastectomy specimen. The patient underwent adjuvant chemotherapy,radiation and endocrine therapy[2]. Here we report the new event after 2 years of follow up.

Figure 1. A: Tumor magnetic resonance imaging, axial; B: intramammary sentinel lymph node magnetic resonance imaging, axial view

CASE REPORT

A 44-year-old, post-menopausal female with a mammogram showing a partially defined lump of the right breast. Breast ultrasound (US) showed a circumscribed hypoechoic lesion, 1.4 × 1.1 cm, 3.8 cm away from the areolar complex, and also an adjacent hypoechoic microlobulated lesion of 1.4 × 1.2 × 1.4 cm, both in the outer quadrants of the right breast. US-guided core-needle biopsy of the lesion revealed a high grade invasive ductal carcinoma (IDC), luminal B (estrogen receptor 30%, progesterone receptor and human epidermal growth factor receptor type 2 negative, and Ki-67 of 80%).

Magnetic resonance imaging (MRI) showed a mass with spiculated contours at early and heterogeneous post-contrast enhancement in the junction of the outer quadrants of the right breast, measuring 1.8 × 1.6 ×1.5 cm [Figure 1A and B]. In addition, a circumscribed oval mass at early and homogeneous post-contrast enhancement, in lower inner quadrant, measuring 9 × 5 × 5 mm and in close contact with the pectoralis muscle, which seemed to correspond to an IMLN. Second-look US was performed directly to this lymph node, which revealed a suspicious cortical thickening and a decreased hilum. A breast conserving surgery of the index lesion, plus radioguided occult lesion localization of the suspicious lesion in the lower inner quadrant and sentinel lymph node biopsy (SLNB), were performed. The pathology report of the lesions identified an IDC, no special type, histology and nuclear grade III and ductal carcinomain situassociated.Three axillary sentinel lymph nodes (SLNs) were free of metastases, however the suspected lesion in the lower inner quadrant resulted in 3 IMLNs, all affected by cancer metastases with ECE [Figure 2A and B].

Published literature for IMLNs does not mention capsular leakage, thus, there is no consensus for the best treatment. Pathologists admitted margins in lymph nodes were not frozen, which did not make it feasible to know if the margins of the additional lesions were disease free. Multidisciplinary recommendation was mastectomy without axillary lymph node dissection (ALND) and immediate breast reconstruction with implants, which was performed two weeks after the patient’s consent in regards to the unknown probability of further disease in the IMLNs. Pathology report revealed no evidence of malignancy. The patient underwent 4 cycles of anthracycline + cyclophosphamide followed by 12 cycles of taxanes and breast +axillary, internal mammary and supraclavicullar drainage chain radiation therapy + tamoxifen. After 2 years of follow up, the patient suddenly developed axillary pain and fistulization accompanied by fever, and sought the emergency room immediately [Figure 3A]. US and breast MRI showed an axillary lymph node with high T2 signaling, measuring 4.0 × 3.6 cm in deep contact with pectoralis muscle and a circumscribed oval mass at early and homogeneous post-contrast enhancement, located in the level 2 of the axilla, measuring 1.0 × 0.9 cm.Removal of the implant and ALND with primary closure of the chest wall was performed. Pathology report showed fragment of fibroadipous and muscular tissue compromised by carcinoma, associated to intense chronic inflammatory process abscessed. Skin and 3 axillary lymph nodes level 2 and 3 free of metastasis[Figure 3B].

Figure 2. A: Intramammary lymph nodes affected by cancer metastases (3/3): capsular extravasation; B: capsular extravasation

Figure 3. A: Clinical presentation of axillary recurrence with fistulization; B: axillary lymph node dissection

DISCUSSION

IMLNs are important because they can be the primary sites of metastasis and SLNs, and when the image is identified, the presence of metastasis is more frequent than in IMLNs detected incidentally[1]. They are involved in a variety of clinical situations, including benign lesions, tumor metastases, breast lymphomas and breast cancer, where their importance is not fully established. Nevertheless, there is evidence that IMLNs are an independent factor for poor prognosis, and they may change therapeutic decisions[3]. Patients with metastatic IMLNs had more aggressive cancers with lymphatic and vascular invasion as well as increased axillary lymph node metastases[4]. In a multicenter study including 33,000 SLN-negative cases from 61 observational series analysis that did not go to ALND reported an axillary recurrence (AR) rate around 0.6%[5]. The NSABP-32 trial showed that SLNB minimized side effects with equivalent survival and regional control than ALND in the SLNB-negative setting and then quickly became the standard of care in early stage breast cancer clinically node-negative[6]. AMAROS trial included 1,425 patients with T1-2 breast cancer, no palpable nodes and positive SLNs. Patients were randomized to ALND or axillary radiotherapy and had a median follow up of 6.1 years. No differences in 5-year AR rate was observed between the ALNDvs.radiotherapy group[7].

A retrospective study from the National Cancer Data Base evaluated women with clinically nodenegative breast cancer who had nodal macro or microscopic metastases in the SLN. There were no significant differences in AR with the addition or not of ALND in macrometastasis (1.2vs.1,P= 0.4) and micrometastasis (0.6vs.0.2,P= 0.063)[8]. When IMLN metastases were identified in the breast specimens, it has been suggested that complete ALND may be based on the axillary SLN negative status and thus, ALND can be avoided in this setting[9]. Even though our case has not demonstrated malignancy at the surgical site, ECE is considered a sign of worse prognosis, and might be the evidence that leads us to the AR of this patient. Moreover, there is not any standard definition of ECE in the literature. Some authors have used “focal”or “extended” definition with no description regarding adjacent sites of invasion eventually[10]. Standard definition of ECE must be identified, because the ECE might be considered by future staging systems[11].

However, it’s impossible to conclude that IMLNs metastases featuring ECE might be an independent outcome factor and its clinical meaning is yet controversial and unknown.

DECLARATIONS

Authors’ contributions

Sample collection: De Alcantara Filho PR, Bezerra SM

Analysis of medical aspects of research, data analysis: De Alcantara Filho PR

Availability of data and materials

All the data in this article is available to the readers.

Financial support and sponsorship

None.

Conflicts of interest

All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate

Patient consented to participate in a research study.

Consent for publication

Not applicable.

Copyright

? The Author(s) 2019.